Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
AnGes’ COVID-19 Vaccine Given Some Safety Confirmation Before Clinical Trial: MHLW Official
A PI/PII clinical trial for AnGes’ novel DNA vaccine for COVID-19 was launched after a certain level of safety was confirmed for the vaccine by the Pharmaceuticals and Medical Devices Agency (PMDA), a senior health minister official said on July…
To read the full story
Related Article
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…